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Abstract
Background:  Both TGF-β1 and VEGF play a critic role in the multiple-step process of
tumorgenesis of gastric cancer. Single nucleotide polymorphisms (SNPs) of the TGFB1 and VEGF
genes have been associated with risk and progression of many cancers. In this study, we investigated
the association between potentially functional SNPs of these two genes and risk of gastric cancer
in a US population.
Methods: The risk associated with genotypes and haplotypes of four TGFB1 SNPs and four VEGF
SNPs were determined by multivariate logistic regression analysis in 171 patients with gastric
cancer and 353 cancer-free controls frequency-matched by age, sex and ethnicity.
Results: Compared with the VEGF-634GG genotype, the -634CG genotype and the combined -
634CG+CC genotypes were associated with a significantly elevated risk of gastric cancer (adjusted
OR = 1.88, 95% CI = 1.24-2.86 and adjusted OR = 1.56, 95% CI = 1.07-2.27, respectively).
However, none of other TGFB1 and VEGF SNPs was associated with risk of gastric cancer.
Conclusion: Our data suggested that the VEGF-634G>C SNP may be a marker for susceptibility
to gastric cancer, and this finding needs to be validated in larger studies.
Background
Gastric cancer is one of the major causes of cancer-related
deaths worldwide, although both incidence and mortality
of gastric cancer have been declining in recent years [1]. In
2008, there were 21,500 new gastric cancer patients, and
10,880 patients died of this disease in the United States
[2]. Epidemiological studies have identified many risk fac-
tors for gastric cancer, including older age, being a man,
Helicobacter pylori (H. pylori) bacteria infection, diets
high in smoked foods, salted fish and meats, and pickled
vegetables, tobacco use and obesity [2]. Although about
two-thirds of gastric cancer could be prevented by chang-
ing lifestyle and diet habits [3], the fact that some individ-
uals develop gastric cancer while others do not when
having similar exposures suggests that genetic factors may
also play an important role in the etiology of gastric can-
cer.
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It has been reported that both TGF-β1 and VEGF played
an important role in the oncogenesis of gastric cancer
[4,5]. Both TGFB1 and VEGF genes are highly polymor-
phic, reportedly having 168 and 140 variants, respec-
tively, but few are within the promoters or coding regions
that may be potentially functional http://
www.ncbi.nlm.nih.gov/SNP/. Of these variants, several
common single nucleotide polymorphisms (SNPs) have
been described as important [6-8] and reported to be
involved in the etiology of various cancers [9-12]. For
example, some TGFB1 and VEGF variants are associated
with protein functions, which may contribute to an indi-
vidual's susceptibility to cancer [13]. Several studies have
investigated the association between TGFB1  and  VEGF
SNPs and risk of cancers, including breast cancer [14-16],
lung cancer [17,18], and gastric cancer [19-22], but the
results were inconsistent.
To investigate the role of TGFB1 and VEGF SNPs in the eti-
ology of gastric cancer, we conducted a case-control study
to evaluate the association between three TGFB1  SNPs
(one promoter SNP -509C>T and two exon 1 SNPs
+869T>C and +915G>C) and three VEGF SNPs (one pro-
moter SNP -1498T>C, one 5'-untranslated region SNP -
634G>C and one 3'-untranslated region SNP +936C>T)
and gastric cancer risk in a US population.
Methods
Study population
The case-control study consisted of 171 patients with
newly diagnosed and histologically confirmed gastric can-
cer at The University of Texas MD Anderson Cancer Center
(Houston, TX) between February 1990 and July 2008. The
353 cancer-free controls subjects were selected from an
ongoing molecular epidemiology study of the head and
neck cancer since 1995 [23] by frequency matching by
age, sex and ethnicity. All cancer-free control subjects were
recruited from persons who were not hospital patients,
nor seeking health care but accompanying the patients
visiting the clinics, and who were genetically unrelated to
the cases. The study protocol and informed consent form
used in this study were approved by our institutional
review board.
Genotyping
Genomic DNA was extracted from the buffy coat fraction
of each blood sample by using a Blood Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer's instruc-
tions. DNA purity and concentrations were determined by
spectrophotometric measurement of absorbance at 260
and 280 nm by UV spectrophotometer.
The selected three TGFB1 SNPs [-509C>T (rs1800469) in
the promoter, +869T>C (rs1800470) and +915G>C
(rs1800471) in the exon 1] and three promoter VEGF
SNPs [-1498T>C (rs833061) in the promoter and -
634G>C (rs2010963) in the 5'-untranslated region, and
VEGF  +936C>T (rs3025039) in the 3'-untranslated
region] were genotyped using polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP)
method. These six SNPs are relatively common (a minor
allele frequency > 0.05) in Caucasian populations. Geno-
types of TGFB1  SNPs were determined as previously
described [24]. Assays on the VEGF -1498T>C (rs833061),
-634G>C (rs2010963), and +936C>T (rs3025039) SNPs
were previously reported [17]
For the PCR-RFLP assay, the genotyping was performed
without knowing the subjects' case and control status, and
almost the same number of cases and controls were
assayed in each 96-well PCR plate. Two research assistants
independently read the gel pictures and performed the
repeated assays, if they did not reach a consensus on the
tested genotype. In addition, 10% of the samples were
randomly selected to perform the repeated assays, and the
results were 100% concordant.
Statistical Analysis
The  χ2 tests were used to compare the distribution of
demographic variables and selected risk factors between
cases and controls. The Hardy-Weinberg equilibrium
(p2+2pq+q2 = 1), where p is the frequency of the variant
allele and q = 1-p, was tested by a goodness-of-fit χ2 test to
compare the observed genotype frequencies with the
expected genotype frequencies in cancer-free controls.
Unconditional logistical regression analysis was used to
calculate odds ratios (ORs) and their 95% confidence
intervals (CIs) with and without adjustment for age, sex,
ethnicity, smoking status and alcohol use. Age was also
dichotomized according to the median age (57 years) of
the controls. The logistic regression model was also used
for the trend test of the genotypes with different number
of the minor alleles. The 2-linkage disequilibrium (LD)
program and Proc ALLELE in SAS/Genetics software were
used to detect the LD of any pair of SNPs. Proc HAPLO-
TYPE in SAS/Genetics software using the expectation-max-
imization (EM) algorithm was applied to generate
maximum likelihood estimates of haplotype frequencies.
Haplotype were combined when their frequency was
<5%. The joint effects of the TGFB1 and VEGF SNPs and
their interactions with smoking and drinking on gastric
cancer risk were also evaluated. Finally, we calculated the
false-positive report probability (FPRP) to test for false-
positive associations, using prior probabilities of 0.0001,
0.001, 0.01, 0.1, and 0.25. The OR was set close to the
observed value obtained in our study, and a probability of
<0.2 was considered a noteworthy association. All statisti-
cal tests were two-sided, with a P value of 0.05 considered
significant, by using SAS software (version 9.1; SAS Insti-
tute, Cary, NC).BMC Gastroenterology 2009, 9:77 http://www.biomedcentral.com/1471-230X/9/77
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Results
Characteristics of the study population
This analysis included 171 gastric cancer cases and 353
cancer-free controls. Because we used frequency match-
ing, there were no significant difference in distributions of
age, sex and ethnicity between the cases and controls (P =
0.135, 0.444 and 0.486, respectively). For the tumor
types, more than 50% of the cases had intestinal type,
about 125 had difuse type, and the remaining was mixed.
There were more current and former smokers in cases
(19.9% and 39.2%, respectively) than in controls (13.6%
and 38.5%, respectively), but the difference was not statis-
tically significant (P = 0.126). However, there were signif-
icantly more alcohol drinkers among cases than among
controls (P = 0.037) (Table 1). These variables were fur-
ther adjusted for in multivariate logistic regression models
to control for any residual effect of their confounding on
the main effect of selected SNPs.
TGFB1 and VEGF genotypes and risk of gastric cancer
The genotype and allele distributions of the three TGFB1
SNPs and three VEGF SNPs between the cases and con-
trols are summarized in Table 2. The observed genotype
frequencies of these SNPs were all in agreement with the
Hardy-Weinberg equilibrium in the control subjects,
except for TGFB1 -509C>T and VEGF -634G>C, indicating
some possible selection bias in the hospital-based con-
trols. Although none of the minor alleles had a different
frequency distribution between the cases and the controls,
the VEGF-634G>C genotype frequencies were statistically
significantly between the cases (40.4% for GG, 42.1% for
CG, and 17.5% for CC) and the controls (51.0% for GG,
28.0% for CG and 21.0% for CC) (P = 0.003) (Table 2).
Further logistic regression analysis revealed that, of the six
SNPs examined, only the VEGF -634CG heterozygous and
the combined -634CG+CC variant genotypes were associ-
ated with a significantly elevated risk of gastric cancer
(adjusted OR = 1.88, 95% CI = 1.24-2.86 and adjusted OR
= 1.56, 95% CI = 1.07-2.27, respectively). In further strat-
ified analysis by age, sex, ethnicity, alcohol use and smok-
ing status, the risk associated with the combined -
634CG+CC variant genotypes was more evident in sub-
groups of ever smokers (adjusted OR = 1.75, 95% CI =
1.06-2.90), never drinker (adjusted OR = 2.00, 95% CI =
1.14-3.54) and non-white subjects (adjusted OR = 2.39,
95% CI = 1.15-4.98) (Table 3). This kind of significant
association was not found for the three TGFB1 SNPs and
other two VEGF SNPs (Table 2).
TGFB1 and VEGF haplotypes and risk of gastric cancer
To further analyze possible combined effects of the TGFB1
and VEGF SNPs, we estimated the haplotypes on the basis
of the observed genotypes. As shown in Table 4, the four
common TGFB1 haplotypes (CTG, CCG, TCG and CCC)
represented 85.6% and 89.9% of the chromosomes of the
controls and cases, respectively. For the VEGF haplotypes,
the common alleles included CGC, TCC, CCC and CGT.
Table 1: Frequency distributions of selected variables in gastric cancer cases and cancer free controls
Cases (n = 171) Controls (n = 353)
Variables n % n % P*
Age (years) 59.7 ± 12.6 57.6 ± 11.2 0.135
≤ 45 24 14.0 47 13.3
45-59 90 52.6 216 61.2
>59 57 33.3 90 25.5
Sex
Female 56 32.7 104 29.5 0.444
Male 115 67.3 249 70.5
Ethnicity
Non-Hispanic White 120 70.2 258 73.1 0.486
Non-White 51 29.8 95 26.9
Smoking status
Current 34 19.9 48 13.6
Former 64 39.2 136 38.5 0.126
Never 70 40.9 169 47.9
Alcohol use
Current 63 36.8 115 32.5
Former 33 19.3 45 12.8 0.037
Never 75 43.9 193 54.7
Tumor type
Intestinal 101 59.1
Diffuse 20 11.7
Mixed 50 29.2
* Two-sided χ2 test.BMC Gastroenterology 2009, 9:77 http://www.biomedcentral.com/1471-230X/9/77
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However, the frequency distributions of these haplotypes
between the cases and controls was not significantly dif-
ferent for both TGFB1 (P = 0.759) and VEGF (P = 0.808),
nor were they associated with risk of gastric cancer.
Finally, because the sample size of this study was small,
we calculated FPRP for the positive findings. We found
that under the assumption of a prior probability of 0.1,
the FPRP of VEGF -634CG vs. -634GG for yielded values
of 0.13, suggesting that the VEGF  -634CG vs. -634GG
findings was noteworthy. However, the FPRPs of VEGF -
634CG+CC vs. -634GG for all subjects, non-whites, ever
smokers and never drinkers yielded values of 0.31, 0.54,
0.49 and 0.38, respectively, which were likely to be false
positive findings. Therefore, our findingds need to be val-
idated in larger studies.
Discussion
Gastric cancer is a genetic disease developing from a mul-
tifactorial, multigenetic and multistage process [25,26]. It
was widely accepted that both genetic and environmental
factors may be involved in the etiology of gastric cancer
Table 2: Genotype frequencies of TGFB1 and VEGF polymorphism gastric cancer cases and controls and their associations with risk of 
gastric cancer
Cases (n = 171) Controls (n = 353)
Genotypes n % n % P† Crude OR
(95% CI)
Adjusted OR (95% CI) * P‡
TGFB1 -509 C >T (rs1800469) 0.404
CC 125 73.1 238 67.4 1.00 1.00
CT 33 19.3 80 22.7 0.79 (0.50-1.24) 0.81 (0.51-1.30) 0.386
TT 13 7.6 35 9.9 0.71 (0.36-1.39) 0.71 (0.36-1.40) 0.323
CT+TT 46 26.9 115 32.6 0.76 (0.51-1.14) 0.78 (0.52-1.18) 0.239
C allele 0.173 0.212 0.246**
TGFB1 869 T >C (rs1800470) 0.805
TT 57 33.3 111 31.4 1.00 1.00
CT 83 48.5 170 48.2 0.95 (0.63-1.44) 1.01 (0.67-1.55) 0.947
CC 31 18.1 72 20.4 0.84 (0.49-1.42) 0.81 (0.48-1.39) 0.448
CT+CC 114 66.7 242 68.6 1.16 (0.73-1.85) 0.92 (0.62-1.35) 0.374
C allele 0.424 0.445 0.727**
TGFB1 915 G >C (rs1800471) 0.447
GG 151 88.3 313 88.7 1.00 1.00
CG 18 10.5 39 11.0 0.96 (0.53-1.73) 0.99 (0.54-1.83) 0.994
CC 2 1.2 1 0.3 4.15 (0.37-46.1) 4.91 (0.43-56.3) 0.201
CG+CC 20 11.7 40 11.3 1.04 (0.59-1.83) 1.09 (0.56-1.96) 0.776
C allele 0.064 0.058 0.715**
VEGF -1498T > C (rs833061) 0.748
TT 51 29.8 111 31.4 1.00 1.00
CT 83 48.6 159 45.0 1.14 (0.74-1.74) 1.12 (0.73-1.74) 0.597
CC 37 21.6 83 23.6 0.97 (0.58-1.62) 0.99 (0.59-1.67) 0.973
CC+CT 120 70.2 242 68.6 1.08 (0.73-1.61) 1.08 (0.72-1.62) 0.715
C allele 0.459 0.460 0.984**
VEGF -634G > C (rs2010963) 0.006
GG 69 40.4 51.0 1.00 1.00
CG 72 42.1 28.0 1.90 (1.26-2.86) 1.88 (1.24-2.86) 0.003
CC 30 17.5 21.0 1.06 (0.64-1.76) 1.10 (0.66-1.85) 0.712
CG+CC 102 59.6 49.0 1.54 (1.06-2.23) 1.56 (1.07-2.27) 0.022
C allele 0.386 0.349 0.491**
VEGF +936C > T (rs3025039) 0.550
CC 127 74.3 78.2 1.00 1.00
CT 41 24.0 19.8 1.27 (0.82-1.97) 1.29 (0.83-2.02) 0.262
TT 3 1.8 2.0 0.93 (0.24-3.66) 1.12 (0.28-4.58) 0.837
CC+CT 44 25.8 21.8 1.24 (0.81-1.90) 1.28 (0.83-1.97) 0.269
T allele 0.137 0.119 0.481**
* Adjusted for age, gender, ethnicity, smoking status and alcohol status in a logistic regression model.
†Two-sided χ 2 test for either genotype distribution or allele frequency.
‡ Two-sided χ 2 test for difference in frequency distribution of genotype between cases and controls by adjusted for age, gender, ethnicity, smoking 
status and alcohol status.
** Two-sided χ 2 tests for the differences in the minor allele frequencies between cases and controlsBMC Gastroenterology 2009, 9:77 http://www.biomedcentral.com/1471-230X/9/77
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[27]. During the multistage carcinogenesis, TGFB1 may be
involved in multiple important cellular processes, play a
biphasic role in carcinogenesis, and inhibit proliferation
of tumors in early stages of cancers, whereas it may also
promote tumor growth and metastasis in later stages of
cancers [28,29]. Several molecular epidemiological stud-
ies have shown an association of TGFB1 SNPs with risk of
various cancers, including breast [14,15,30,31], prostate
[32,33] and hepatocellular carcinoma [34,35] and gastric
cancer [4,19].
The roles of -509C>T, +869T>C and +915G>C SNPs in
TGFB1 have been implicated in the etiology of various
human cancers. For example, in high-risk Chinese popu-
lations, TGFB1 -509C>T was associated with a reduced
risk of gastric cancer [19] and the -509T variant genotypes
were found to be associated with a decreased risk of
among stage I+II cases [20]. In the present study, we did
not observe a significant association between TGFB1 SNPs
and gastric cancer risk, partly because our study size was
small. Another possible explanation is that there may be
an ethnicity difference in the etiology of gastric cancer. For
example, the H. pylori infection was common in Asians
but not in Caucasians [36], which may interact with
genetic factors. Furthermore, cancer is a disease involving
multiple genes/SNPs, and therefore the combined analy-
sis of multiple gene or haplotype-based approach might
be more powerful than the analysis of single allele or
locus effect [19], which requires studies with much large
sample sizes. It is also likely that our results could be
biased owing to possible selection biases in hospital-
based case-control studies. Therefore, larger studies are
warranted to further test whether the TGFB1 variants are
associated with gastric cancer risk.
Among other genetic factors, VEGF, the key mediator of
angiogenesis, also plays an important role in the develop-
ment of different kind of tumors, including gastric cancer.
Several studies have investigated the associations between
Table 3: Stratification analysis of gastric cancer risk associated with the VEGF -634 G>C genotype frequencies
Cases (n = 171) Controls (n = 353) Adjusted OR (95% CI)*
Variables GG
N (%)
CG+CC
N (%)
GG
N (%)
CG+CC
N (%)
GG CG+CC P†
Age (years)
≤ 57 30 (42.3) 41 (57.7) 95 (52.8) 85 (47.2) 1.00 1.50 (0.84-2.64) 0.160
> 57 39 (39.0) 61 (61.0) 85 (49.1) 88 (50.9) 1.00 1.58 (0.95-2.63) 0.080
Sex
Female 18 (32.1) 38 (67.9) 49 (47.1) 55 (52.9) 1.00 1.86 (0.94-3.69) 0.075
Male 51 (44.4) 64 (55.6) 131 (52.6) 118 (47.4) 1.00 1.44 (0.91-2.28) 0.116
Ethnicity
Hispanic White 53 (44.2) 67 (55.8) 129 (50.0) 129 (50.0) 1.00 1.32 (0.85-2.06) 0.219
Non-white 16 (31.4) 35 (68.6) 51 (53.7) 44 (46.3) 1.00 2.39 (1.15-4.98) 0.020
Smoking status
Never 27 (38.6) 43 (61.4) 79 (46.7) 90 (53.3) 1.00 1.33 (0.75-2.38) 0.336
Ever 42 (41.6) 59(58.4) 101 (54.9) 83 (45.1) 1.00 1.74 (1.06-2.90) 0.032
Drinking status
Never 25 (33.3) 50 (66.7) 99 (51.3) 94 (48.7) 1.00 2.00 (1.14-3.54) 0.017
Ever 44 (45.8) 52 (54.2) 81 (50.6) 79 (49.4) 1.00 1.24 (0.74-2.07) 0.411
* Adjusted for age, sex, ethnicity, smoking status and alcohol status in a logistic regression model where it was appropriate.
†Two-sided χ 2 test for the ORs obtained from the multivariate logistic regression with adjustment for age, sex, ethnicity, smoking status and 
alcohol status
Table 4: Frequency distribution of the TGFB1 and VEGF 
haplotype alleles between gastric cancer cases and controls and 
their associations with risk of Gastric Cancer
Cases Controls
Genotypes n % n % Crude OR
(95% CI) *
P**
TGFB1 alleles (No. of variant alleles)†
C-T-G 194 46.0 387 40.0 1.29 (0.12-13.7) 0.830
C-C-G 107 25.4 216 24.6 1.26 (0.11-13.9) 0.851
T-C-G 56 13.3 144 16.4 1.93 (0.17-21.8) 0.594
C-C-C 22 5.21 40 4.6 0.87 (0.06-13.6) 0.919
VEGF alleles (No. of variant alleles)‡
C-G-C 135 24.6 278 30.0 0.56 (0.02-18.0) 0.744
T-C-C 115 20.9 200 21.6 0.42 (0.02-13.6) 0.621
C-C-C 65 11.8 90 9.7 0.46 (0.01-19.9) 0.686
C-G-T 35 6.4 45 4.9 0.25 (0.01-12.2) 0.482
* Calculated by using the most common haplotype as the reference. 
Ors represent the risk per copy of each haplotype.
† The number of TGFB1 haplotype alleles; the variant (risk) alleles 
used for calculation were-509T, 869C or 915C.
‡ The number of VEGF haplotype alleles; the variant (risk) alleles used 
for calculation were -1498C, -634C or 936T.
**Two-sided χ 2 test for the ORs obtained from the multivariate 
logistic regression with adjustment for age, sex, ethnicity, smoking 
status and alcohol statusBMC Gastroenterology 2009, 9:77 http://www.biomedcentral.com/1471-230X/9/77
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VEGF SNPs and risk of cancers, including breast, lung and
gastric cancers [16,17,21,22,37], However, the results
from published studies remain inconsistent rather than
conclusive. Recently, Ke Q et al [21] found that none of
four potentially functional SNPs (-2578C>A, -1498T>C, -
634G>C, and +936C>T) of the VEGF gene or their haplo-
types achieved a significant difference in their distribu-
tions between gastric cancer cases and controls in a
Chinese population, whereas in a Greek study of the asso-
ciation between these four potentially functional SNPs in
VEGF and gastric cancer risk in 100 cases and 100 controls
[38], it was found that the -634CC variant genotype was
associated with an increased the risk of gastric cancer with
a marginal significance. However, the -634CC was shown
to be associated with a significantly decreased risk of gas-
tric cancer in a Korean population [22]. Our current study
indicated that the heterozygous -634CG and the com-
bined -634CG+CC carriers had an increased risk of gastric
cancer when compared with the -634GG genotype. Again,
these studies demonstrated some possible ethnic differ-
ence in the etiology of gastric cancer [19].
An obvious limitation in the present study was the lack of
information on the H. pylori infection status of the sub-
jects. Because H. pylori infection was relatively rare in the
US compared with Asian countries, these patients were
not tested for H. pylori infection upon their visit to the
hospital. This defect of the study has to be corrected in
future well-planned studies. Also, we observed that
genetic effects were more profound in never drinkers in
this study population, a phenomenon we often observed
in our association studies, in which the risk associated
with adverse genotypes appears to be higher in non-
exposed or less exposed subjects, suggesting that the
related susceptibility to cancer may be high in such sub-
groups. Alternatively, there may be some unknown risk
factors that were not identified in these subgroups.
Conclusion
In this hospital-based case-control study of sporadic gas-
tric cancer, our finding supports the notion that variant
genotypes of the VEGF-634C>G polymorphism, but not
other tested SNPs, may contribute to gastric cancer risk.
However, because we used a hospital-based case-control
study design, the observed associations may have been
biased or simply due to chances. Therefore, larger, pro-
spective studies, particularly with the information about
H. pylori infection, are needed to verify our findings.
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